Clinical Trial Update: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of APG-115 alone or with pembrolizumab in metastatic melanoma and other advanced solid tumors; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Malignant Peripheral Nerve Sheath Tumor
• Melanoma
• Mucosal Melanoma
• Uveal Melanoma

Drugs mentioned

• APG-115 (APG-115)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING